Close Menu

NEW YORK (GenomeWeb) – Cancer diagnostics firm Pillar Biosciences has partnered with Illumina to develop next-generation sequencing-based in vitro diagnostics, the companies announced today.

Under the terms of the deal, Pillar will use its stem loop inhibition-mediated amplification (SLIMamp) technology — which is designed for amplifying overlapping or tiled amplicons in a single multiplex PCR reaction — to develop diagnostics that run on Illumina's MiSeqDx instrument.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.